Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: A possible new immune intervention

Vincenzo Bottari, A. Frezzolini, M. Ruffelli, P. Puddu, L. Fontana, O. De Pità

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease frequently associated with asthma, rhinitis, and food allergy. Lymphocytes producing Th2-type cytokines (such as interleukin [IL]-3, IL-4, and IL-5) have been thought to have a key role in the pathogenesis of the disease. We have recently demonstrated that elevated serum levels of the soluble form of CD30 (sCD30), an activation marker of Th2-cell clones, correlates with disease activity in pediatric patients suffering from AD. Clinical trials have demonstrated that cyclosporin A (CyA) treatment resulted in significant improvement of clinical symptoms in patients affected with AD. In this study, we evaluated the role of CyA in modulating sCD30 release in a group of adult patients affected by severe AD treated with CyA at the dosage of 3.5 mg/kg body weight for 12 weeks. Our results demonstrated, in parallel with an improvement of clinical symptoms, a significant reduction of serum levels of both IL-4 and sCD30, thus suggesting that CyA can prevent the activation of Th2 cells observed in AD.

Original languageEnglish
Pages (from-to)507-510
Number of pages4
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume54
Issue number5
DOIs
Publication statusPublished - 1999

Fingerprint

Atopic Dermatitis
Cyclosporine
Serum
Th2 Cells
Interleukin-4
Food Hypersensitivity
Interleukin-3
Interleukin-5
Rhinitis
Skin Diseases
Asthma
Clone Cells
Body Weight
Clinical Trials
Lymphocytes
Pediatrics
Cytokines

Keywords

  • Atopic dermatitis
  • Cyclosporin A
  • sCD30
  • Th2 immune response

ASJC Scopus subject areas

  • Immunology

Cite this

Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis : A possible new immune intervention. / Bottari, Vincenzo; Frezzolini, A.; Ruffelli, M.; Puddu, P.; Fontana, L.; De Pità, O.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 54, No. 5, 1999, p. 507-510.

Research output: Contribution to journalArticle

Bottari, Vincenzo ; Frezzolini, A. ; Ruffelli, M. ; Puddu, P. ; Fontana, L. ; De Pità, O. / Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis : A possible new immune intervention. In: Allergy: European Journal of Allergy and Clinical Immunology. 1999 ; Vol. 54, No. 5. pp. 507-510.
@article{ec7fc6046a294bb6bef4663804b0c314,
title = "Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: A possible new immune intervention",
abstract = "Atopic dermatitis (AD) is a chronic inflammatory skin disease frequently associated with asthma, rhinitis, and food allergy. Lymphocytes producing Th2-type cytokines (such as interleukin [IL]-3, IL-4, and IL-5) have been thought to have a key role in the pathogenesis of the disease. We have recently demonstrated that elevated serum levels of the soluble form of CD30 (sCD30), an activation marker of Th2-cell clones, correlates with disease activity in pediatric patients suffering from AD. Clinical trials have demonstrated that cyclosporin A (CyA) treatment resulted in significant improvement of clinical symptoms in patients affected with AD. In this study, we evaluated the role of CyA in modulating sCD30 release in a group of adult patients affected by severe AD treated with CyA at the dosage of 3.5 mg/kg body weight for 12 weeks. Our results demonstrated, in parallel with an improvement of clinical symptoms, a significant reduction of serum levels of both IL-4 and sCD30, thus suggesting that CyA can prevent the activation of Th2 cells observed in AD.",
keywords = "Atopic dermatitis, Cyclosporin A, sCD30, Th2 immune response",
author = "Vincenzo Bottari and A. Frezzolini and M. Ruffelli and P. Puddu and L. Fontana and {De Pit{\`a}}, O.",
year = "1999",
doi = "10.1034/j.1398-9995.1999.00958.x",
language = "English",
volume = "54",
pages = "507--510",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis

T2 - A possible new immune intervention

AU - Bottari, Vincenzo

AU - Frezzolini, A.

AU - Ruffelli, M.

AU - Puddu, P.

AU - Fontana, L.

AU - De Pità, O.

PY - 1999

Y1 - 1999

N2 - Atopic dermatitis (AD) is a chronic inflammatory skin disease frequently associated with asthma, rhinitis, and food allergy. Lymphocytes producing Th2-type cytokines (such as interleukin [IL]-3, IL-4, and IL-5) have been thought to have a key role in the pathogenesis of the disease. We have recently demonstrated that elevated serum levels of the soluble form of CD30 (sCD30), an activation marker of Th2-cell clones, correlates with disease activity in pediatric patients suffering from AD. Clinical trials have demonstrated that cyclosporin A (CyA) treatment resulted in significant improvement of clinical symptoms in patients affected with AD. In this study, we evaluated the role of CyA in modulating sCD30 release in a group of adult patients affected by severe AD treated with CyA at the dosage of 3.5 mg/kg body weight for 12 weeks. Our results demonstrated, in parallel with an improvement of clinical symptoms, a significant reduction of serum levels of both IL-4 and sCD30, thus suggesting that CyA can prevent the activation of Th2 cells observed in AD.

AB - Atopic dermatitis (AD) is a chronic inflammatory skin disease frequently associated with asthma, rhinitis, and food allergy. Lymphocytes producing Th2-type cytokines (such as interleukin [IL]-3, IL-4, and IL-5) have been thought to have a key role in the pathogenesis of the disease. We have recently demonstrated that elevated serum levels of the soluble form of CD30 (sCD30), an activation marker of Th2-cell clones, correlates with disease activity in pediatric patients suffering from AD. Clinical trials have demonstrated that cyclosporin A (CyA) treatment resulted in significant improvement of clinical symptoms in patients affected with AD. In this study, we evaluated the role of CyA in modulating sCD30 release in a group of adult patients affected by severe AD treated with CyA at the dosage of 3.5 mg/kg body weight for 12 weeks. Our results demonstrated, in parallel with an improvement of clinical symptoms, a significant reduction of serum levels of both IL-4 and sCD30, thus suggesting that CyA can prevent the activation of Th2 cells observed in AD.

KW - Atopic dermatitis

KW - Cyclosporin A

KW - sCD30

KW - Th2 immune response

UR - http://www.scopus.com/inward/record.url?scp=0033022209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033022209&partnerID=8YFLogxK

U2 - 10.1034/j.1398-9995.1999.00958.x

DO - 10.1034/j.1398-9995.1999.00958.x

M3 - Article

C2 - 10380784

AN - SCOPUS:0033022209

VL - 54

SP - 507

EP - 510

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 5

ER -